MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/kead502

Медицинская библиотека · Rheumatology (Oxford, England) · 2023

Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis.

Kerekes György, Czókolyová Monika, Hamar Attila, Pusztai Anita, Tajti Gábor, Katkó Mónika, Végh Edit, Pethő Zsófia, Bodnár Nóra, Horváth Ágnes, Soós Boglárka, Szamosi Szilvia, Hascsi Zsolt, Harangi Mariann, Hodosi Katalin, Panyi György, Seres Tamás, Szűcs Gabriella, Szekanecz Zoltán

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy.

METHODS

Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by 18F-fluorodeoxyglucose-PET/CT.

RESULTS

One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05).

CONCLUSIONS

Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated.

Для цитирования: Kerekes György, Czókolyová Monika, Hamar Attila, Pusztai Anita, Tajti Gábor, Katkó Mónika, Végh Edit, Pethő Zsófia, Bodnár Nóra, Horváth Ágnes, Soós Boglárka, Szamosi Szilvia, Hascsi Zsolt, Harangi Mariann, Hodosi Katalin, Panyi György, Seres Tamás, Szűcs Gabriella, Szekanecz Zoltán. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis.. Rheumatology (Oxford, England). 2023. DOI: 10.1093/rheumatology/kead502.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.